Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety and Efficacy of RX-10100 to Treat Major Depressive Disorder (MDD)

This study has been completed.
Information provided by (Responsible Party):
Rexahn Pharmaceuticals, Inc. Identifier:
First received: January 6, 2011
Last updated: November 18, 2013
Last verified: November 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2011
  Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)